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were identified. After removing duplicates, 1,525 citations were screened. Of these, 
159 full text references were reviewed and 85 systematic reviews met predefined 
inclusion criteria. Five QA methods were most commonly employed: Newcastle-
Ottawa Quality Assessment Scale (NOS) or modified NOS (28%); checklists devel-
oped by authors (15%); the Cochrane checklist or modified version (11%); modified 
checklists from other authors (5%); applying disease-specific QA tools (5%). The 
reliability and applicability of the most commonly employed tool in this research 
field, NOS, were questioned in included reviews, corresponding with concerns on the 
validity of the NOS reported in recently published literature of research methodol-
ogy. ConClusions: The available evidence demonstrates a lack of consensus on 
the use of QA tools for non-RCTs assessing surgical interventions. Various methods 
have been adapted or newly developed by researchers, and the most commonly 
applied QA tool (NOS) may not be fit for purpose in this field of research. There is 
an urgent need for a validated QA tool to appraise the quality of evidence to help 
inform evidence-based decision making on the use of surgical devices and types 
of surgical approaches.
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objeCtives: Scientific analyses with claims data such as burden of disease analyses 
are often based on incidence and prevalence estimates. Latest methodological con-
siderations indicate that the diagnosis-free observation period should be extended 
as much as possible to not overestimate the incidence in chronic diseases. Aim of 
this study was to evaluate the impact of expanding the diagnosis timeframe for 
the incidence as well as the prevalence estimates. Methods: This methodologi-
cal analysis focused on the chronic diseases diabetes mellitus (DM) and multiple 
sclerosis (MS) in 2013 in Germany and was based on anonymized data from the 
Health Risk Institute Research Database. Patients continuously insured for six years 
(2008-2013) were included in the study (n= 3,026,154). Incidence changes due to dif-
ferent diagnosis-free intervals before a diagnosis in 2013 (1 to 5 years) were assessed. 
Correspondingly, the prevalence estimation for 2013 was varied by expanding the 
timeframe for diagnosis from 1 year up to 5 years, as it was assumed that chronic 
diseases identified in previous years persist until 2013. Moreover, disease-specific 
validation of the diagnosis codes was applied as sensitivity analysis. Results: DM 
incidence was 24% higher when a 1-year diagnosis-free observation period was 
applied compared to 5 years (25% in MS). When expanding the prevalence timeframe 
up to 5 years, the prevalence estimation increased by 14% in DM and 21% in MS, 
respectively. The relative proportion of incidence to prevalence also changed by 
varying the utilized timeframe. Out of the prevalent diabetes patients in 2013 10.1% 
were incident when a 1-year timeframe was considered, whereas 7.3% were incident 
when 5 years were applied (11.7% and 7.9% in MS, respectively). ConClusions: 
The methodological concepts should coincide when estimating both the incidence 
and the prevalence of chronic diseases in claims data. Estimates may be biased 
especially when only short timeframes are utilized.
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objeCtives: The ICD-9-CM coding system does not differentiate between small cell 
lung cancers (SCLC) and NSCLC, which poses a challenge for database research on 
forms of lung cancer. We examined the accuracy of an algorithm designed to identify 
likely NSCLC cases among lung cancer patients in a claims-database. Methods: 
Lung cancer patients were selected from the HealthCore Integrated Research 
Environment (HIRE)-Oncology database which combines US administrative claims 
database, and the clinical oncology data (type, stage, etc.) on lung cancer patients. 
Index event was defined as the patient’s first lung cancer diagnosis during 6/1/14 
to 1/31/15 in the claims database. Eligibility criteria were; ≥ 1 lung cancer diagnosis 
& > 12 months continuous pre-index enrolment in the claims database; and pres-
ence in the oncology database. A treatment regimen algorithm was used to iden-
tify NSCLC patients from claims data. This was assessed against the cancer type 
information from the oncology database. Diagnostic accuracy of the algorithm was 
assessed using statistical measures; Sensitivity, Specificity, False Positive Fraction 
(FPF), Positive Predictive Validity (PPV), Negative Predictive Validity (NPV), Positive 
Likelihood Ratio (LR+), Negative Likelihood Ratio (LR-), Diagnostic Odds Ratio (DOR), 
and Agreement (kappa:k). Results: 585 lung cancer patients (mean age = 62, 53% 
male) met all eligibility criteria for analysis. The algorithm classified 464 (79%) 
patients as NSCLC and 121 (21%) as SCLC; whereas, the clinical data classified 513 
(88%) patients as NSCLC and 72 (12%) as SCLC. Algorithm sensitivity was 86% and 
specificity was 71%. The FPF = .29%, PPV= 96%, and NPV= 42%. LR+ = 2.96; LR- = 0.19; 
and DOR= 15.37. Chance adjusted k = .60. ConClusions: The algorithm showed 
good statistical properties for identifying NSCLC patients in claims data except 
for a high false positive fraction. Future research should focus on improving the 
algorithm’s specificity.
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lowed in the majority of manufacturer submissions where supplementary searches 
were conducted. However, the results from this study are limited due to the low 
number of appendices published online. Supplementary search methods used in 
manufacturer submissions should be reported in full and ERGs should be consist-
ent with critique of supplementary search methodology to ensure no evidence is 
omitted in decision making.
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objeCtives: Create a step-wise process to mitigate data collection errors and miss-
ing data during all phases of prospective and retrospective observational stud-
ies. Methods: Based on three multinational retrospective chart review studies 
and two multinational time and motion (T&M) studies completed in 2015, key fac-
tors were identified during all study phases (design, implementation, conduct, and 
analysis) that could lead to data collection errors and missing data. For both meth-
odologies, we designed a step-wise process to help identify risk factors and provide 
effective solutions to improve data quality. Results: During study design, study 
variables should unequivocally be defined with terminology/semantics matching 
the source document (e.g., medical chart) or what is observed in the real-world. 
Differences between countries need to be considered. Training using real-time dem-
onstration of electronic data collection (EDC) tool using examples of de-identified 
patient data is critical for chart reviews. For T&M studies, observers must be trained 
on accurate data measurement and recording. For a chart review using an EDC 
tool, logic and edit checks should be built into the EDC tool to limit data errors and 
incomplete data at entry. For a T&M design, speed of data transmission and fast 
quality control is essential to allow recall by the data observer. Queries for missing 
data or outliers should be phrased objectively and clearly. Effectiveness of quality 
control mechanisms needs to be assessed particularly at the start of data collection, 
and retraining performed, if needed. ConClusions: Limiting data collection errors 
and data incompleteness starts at study design. Essential components of a step-wise 
process include appropriate variable selection and description (terminology/seman-
tics), (re)training, and tailored quality control mechanisms. If such steps are fol-
lowed, data collected would result in a more accurate dataset, therefore improving 
the overall quality of study data and precision of study results.
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objeCtives: Polycystic ovary syndrome (PCOS) is one of the most common female 
endocrine disorders. It presents with a broad range of symptoms and has significant 
and diverse clinical implications. In order to develop a comprehensive understand-
ing of PCOS, a (conceptual) disease model was developed. Methods: The disease 
model was generated based on three lines of concept evaluation research; (1) a 
targeted literature review, (2) interviews with clinical experts; (3) concept elicita-
tion interviews with patients, for which data was recorded, transcribed and coded. 
Collectively, this provided a comprehensive list of the sign, symptom and impact 
concepts most important and relevant to women with PCOS. Results: Nineteen 
peer-reviewed articles were included in the literature review. Five clinical experts 
(USA, Turkey, Netherlands) and 20 PCOS patients (mean (SD) age 29.2 (5.9) years) were 
included in 1:1 qualitative interviews. Concept saturation was observed in patient 
interviews. Significant overlap was seen in the sign, symptom and impact concepts 
of PCOS across the three lines of evidence. Signs/symptoms were categorized into 
pain, infertility, hirsutism, alopecia, acne, menstruation (e.g. irregular menstrua-
tion, heavy bleeding), bloating, weight-related (e.g. weight gain, fluctuations), and 
metabolic abnormality (i.e., obesity, difficulty with weight loss, etc) symptoms. 
Some symptoms, such as pain at non-menstrual times, were uniquely reported 
by patients. Impacts of PCOS included sleep disturbance, emotional functioning, 
social role functioning and physical functioning. Compensatory behaviours (e.g. hair 
removal, diet changes, use of medication) were common. The relationship between 
these concepts is presented in a disease model. ConClusions: This is the first 
known comprehensive disease model for PCOS. It shows many of the defining fea-
tures of the condition can only be accurately and reliably captured by asking patients 
how they feel and function. This work underscores the need for measurement of 
PCOS from the patient perspective using a patient reported outcome (PRO).
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objeCtives: Evaluating the effectiveness and safety of surgical techniques, opera-
tions, and involved medical devices is relatively difficult, sometimes unethical, 
with randomised controlled trials (RCTs). Non-randomised designs are commonly 
applied and used to inform decision making. Quality assessment (QA) methods for 
these studies have previously been reviewed, but not specifically for their appli-
cability to non-RCTs in surgical interventions. The objectives of this systematic 
review were to evaluate which QA tools have been used in this research field and to 
critically appraise these tools. Methods: We systematically searched three elec-
tronic databases (MEDLINE, Embase and Cochrane Library) and Health Technology 
Assessments. Systematic reviews appraising the quality of non-RCTs on surgical 
interventions were included. Results: In total, 1,741 potentially relevant citations 
